{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T21:12:43Z","timestamp":1788556363034,"version":"build-2803163510"},"reference-count":51,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Breathe"],"accepted":{"date-parts":[[2025,1,21]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and fatal interstitial fibrosing disease and, despite some well-known risk factors, its cause is still unknown. Cough is experienced by most patients and is commonly chronic and refractory, having a significant impact on quality of life. Its aetiology is complex, combining factors related to interstitial lung disease (ILD) such as an increased sensitivity of cough-sensitive nerves, structural lung changes and inflammation, genetic factors, several comorbidities and medication-adverse effects. Despite the therapeutic advancements in IPF over the past decade with the introduction of antifibrotic drugs that slow disease progression, effective treatment options for cough in IPF remain unavailable. Cough management often relies on empirical approaches based on studies involving chronic cough patients of unspecified causes and ILD physicians\u2019 personal experiences. Different classes of medications have been tried over time and, more recently, the focus has turned to neuromodulators and opioids, but several studies have shown suboptimal efficacy in cough. On the other hand, these drugs are associated with significant physical, psychological and economic burdens. However, the future brings us hope to the extent that most current ongoing clinical trials are using new molecules and some have demonstrated promising antitussive effects. This review aims to provide a practical guide to understanding and managing cough in IPF patients, presenting pharmacological and non-pharmacological approaches over time, as well as those treatments that are currently being investigated in clinical settings.<\/jats:p>","DOI":"10.1183\/20734735.0176-2024","type":"journal-article","created":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:35:16Z","timestamp":1744878916000},"page":"240176","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Cough in idiopathic pulmonary fibrosis: what is new"],"prefix":"10.1183","volume":"21","author":[{"given":"Marta Alexandra","family":"Carvalho da Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-8035","authenticated-orcid":false,"given":"Rui Miguel","family":"Mouro de Santos Rolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Joana","family":"Pereira Catarata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Filipa","family":"de Sousa Antunes Dias Padr\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,4,17]]},"reference":[{"key":"2025041701351317000_21.2.240176.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30866-8"},{"key":"2025041701351317000_21.2.240176.2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2025041701351317000_21.2.240176.3","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1513\/AnnalsATS.202302-174OC","article-title":"The burden and impact of cough in patients with idiopathic pulmonary fibrosis: an analysis of the prospective observational PROFILE study","volume":"20","author":"Saunders","year":"2023","journal-title":"Ann Am Thorac Soc"},{"key":"2025041701351317000_21.2.240176.4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00408-023-00653-3","article-title":"Assessment and management of cough in idiopathic pulmonary fibrosis: a narrative review","volume":"201","author":"Liu","year":"2023","journal-title":"Lung"},{"key":"2025041701351317000_21.2.240176.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2011.01996.x"},{"key":"2025041701351317000_21.2.240176.6","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S2213-2600(16)30150-3","article-title":"Cough in idiopathic pulmonary fibrosis: more than just a nuisance","volume":"4","author":"Vigeland","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2025041701351317000_21.2.240176.7","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1164\/rccm.202311-2101OC","article-title":"Epidemiology and prognostic significance of cough in fibrotic interstitial lung disease","volume":"210","author":"Khor","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025041701351317000_21.2.240176.8","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1164\/rccm.202311-2169LE","article-title":"Cough severity visual analog scale assesses cough burden and predicts survival in idiopathic pulmonary fibrosis","volume":"209","author":"Wu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2025041701351317000_21.2.240176.9","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.chest.2021.05.071","article-title":"Managing cough in idiopathic pulmonary fibrosis","volume":"160","author":"Wakwaya","year":"2021","journal-title":"Chest"},{"key":"2025041701351317000_21.2.240176.10","doi-asserted-by":"crossref","first-page":"EVIDe2300126","DOI":"10.1056\/EVIDe2300126","article-title":"Managing chronic cough associated with idiopathic pulmonary fibrosis - will nalbuphine fill an unmet need?","volume":"2","author":"Irwin","year":"2023","journal-title":"NEJM Evid"},{"key":"2025041701351317000_21.2.240176.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2025041701351317000_21.2.240176.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2025041701351317000_21.2.240176.13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-020-1298-1","article-title":"Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS trials","volume":"21","author":"Kreuter","year":"2020","journal-title":"Respir Res"},{"key":"2025041701351317000_21.2.240176.14","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-143"},{"key":"2025041701351317000_21.2.240176.15","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0090-2015"},{"key":"2025041701351317000_21.2.240176.16","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219699"},{"key":"2025041701351317000_21.2.240176.17","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.158.6.9804105"},{"key":"2025041701351317000_21.2.240176.18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/MCP.0000000000000697","article-title":"Obstructive sleep apnea in pulmonary fibrosis","volume":"26","author":"Schiza","year":"2020","journal-title":"Curr Opin Pulm Med"},{"key":"2025041701351317000_21.2.240176.19","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00408-022-00589-0","article-title":"Tackling the neuropathic cough of idiopathic pulmonary fibrosis (IPF): more needs to be done","volume":"200","author":"Chung","year":"2022","journal-title":"Lung"},{"key":"2025041701351317000_21.2.240176.20","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.chest.2018.06.038","article-title":"Treatment of interstitial lung disease-associated cough","volume":"154","author":"Birring","year":"2018","journal-title":"Chest"},{"key":"2025041701351317000_21.2.240176.21","doi-asserted-by":"crossref","first-page":"751798","DOI":"10.3389\/fresc.2021.751798","article-title":"Cough in idiopathic pulmonary fibrosis","volume":"2","author":"Mann","year":"2021","journal-title":"Front Rehabil Sci"},{"key":"2025041701351317000_21.2.240176.22","doi-asserted-by":"publisher","DOI":"10.1378\/chest.15-1271"},{"key":"2025041701351317000_21.2.240176.23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60776-4"},{"key":"2025041701351317000_21.2.240176.24","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlg.0000244377.60334.e3"},{"key":"2025041701351317000_21.2.240176.25","doi-asserted-by":"publisher","DOI":"10.1002\/lary.25978"},{"key":"2025041701351317000_21.2.240176.26","doi-asserted-by":"crossref","first-page":"EVIDoa2300083","DOI":"10.1056\/EVIDoa2300083","article-title":"Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis","volume":"2","author":"Maher","year":"2023","journal-title":"NEJM Evid"},{"key":"2025041701351317000_21.2.240176.27","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1164\/rccm.202201-0083ED","article-title":"Chronic cough in idiopathic pulmonary fibrosis: the same difference?","volume":"205","author":"Morice","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025041701351317000_21.2.240176.28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S2213-2600(23)00432-0","article-title":"Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial","volume":"12","author":"Wu","year":"2024","journal-title":"Lancet Respir Med"},{"key":"2025041701351317000_21.2.240176.29","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-BTSabstracts.21"},{"key":"2025041701351317000_21.2.240176.30","unstructured":"Maher T . A phase 2, double-blind, randomized, placebo-controlled, two-treatment, two-period crossover efficacy and safety study in idiopathic pulmonary fibrosis with nalbuphine ER tablets for the treatment of cough. research study. IRAS ID 262846. Trevi Therapeutics, Inc. Eudract number 2028-004744-31. NHS Health Research authority. 2019. https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/tr12-ph-2-study-in-idiopathic-pulmonary-fibrosis-nalbuphine-er-tablets\/"},{"key":"2025041701351317000_21.2.240176.31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.rmed.2016.12.016","article-title":"Etiology and treatment of cough in idiopathic pulmonary fibrosis","volume":"123","author":"Vigeland","year":"2017","journal-title":"Respir Med"},{"key":"2025041701351317000_21.2.240176.32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.pupt.2019.03.008","article-title":"Idiopathic pulmonary fibrosis-associated cough: mechanisms and management","volume":"56","author":"Myall","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"2025041701351317000_21.2.240176.33","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S2213-2600(17)30310-7","article-title":"A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial","volume":"5","author":"Birring","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2025041701351317000_21.2.240176.34","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1164\/rccm.202106-1485OC","article-title":"Phase 2B study of inhaled RVT-1601 for chronic cough in idiopathic pulmonary fibrosis: a multicenter, randomized, placebo-controlled study (SCENIC Trial)","volume":"205","author":"Martinez","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025041701351317000_21.2.240176.35","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-6-201209180-00003"},{"key":"2025041701351317000_21.2.240176.36","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.135947"},{"key":"2025041701351317000_21.2.240176.37","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1513\/AnnalsATS.202103-266OC","article-title":"Azithromycin for the treatment of chronic cough in idiopathic pulmonary fibrosis: a randomized controlled crossover trial","volume":"18","author":"Guler","year":"2021","journal-title":"Ann Am Thorac Soc"},{"key":"2025041701351317000_21.2.240176.38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.pupt.2016.08.001","article-title":"Antitussive effect of carcainium chloride in patients with chronic cough and idiopathic interstitial pneumonias: a pilot study","volume":"40","author":"Lavorini","year":"2016","journal-title":"Pulm Pharmacol Ther"},{"key":"2025041701351317000_21.2.240176.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61255-1"},{"key":"2025041701351317000_21.2.240176.40","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00284-2020"},{"key":"2025041701351317000_21.2.240176.41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s41030-021-00162-9","article-title":"Treatment of persistent cough in subjects with idiopathic pulmonary fibrosis (IPF) with Gefapixant, a P2X3 antagonist, in a randomized, placebo-controlled clinical trial","volume":"7","author":"Martinez","year":"2021","journal-title":"Pulm Ther"},{"key":"2025041701351317000_21.2.240176.42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00408-022-00592-5","article-title":"A randomized, double-blind, placebo-controlled, parallel-group phase 2b trial of P2X3 receptor antagonist sivopixant for refractory or unexplained chronic cough","volume":"201","author":"McGarvey","year":"2023","journal-title":"Lung"},{"key":"2025041701351317000_21.2.240176.43","first-page":"A7396","article-title":"BLU-5937 a highly selective P2X3 homotrimeric receptor antagonist with improved taste safety profile in healthy subjects","volume":"199","author":"Garceau","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"2025041701351317000_21.2.240176.44","first-page":"A5608","article-title":"Improvements in cough severity and quality of life in SOOTHE, a phase 2b, dose finding trial of BLU-5937 in refractory chronic cough","volume":"205","author":"Birring","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2025041701351317000_21.2.240176.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.01.038"},{"key":"2025041701351317000_21.2.240176.46","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1164\/rccm.201704-0769OC","article-title":"XEN-D0501, a novel transient receptor potential vanilloid 1 antagonist, does not reduce cough in patients with refractory cough","volume":"196","author":"Belvisi","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2025041701351317000_21.2.240176.47","first-page":"A2532","article-title":"Randomized proof-of-concept study of AX-8, a TRPM8 agonist, in refractory or unexplained chronic cough","volume":"207","author":"Smith","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2025041701351317000_21.2.240176.48","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1164\/rccm.202006-2359OC","article-title":"Aprepitant for cough in lung cancer. A randomized placebo-controlled trial and mechanistic insights","volume":"203","author":"Smith","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2025041701351317000_21.2.240176.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2019.08.001"},{"key":"2025041701351317000_21.2.240176.50","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2019.PA600"},{"key":"2025041701351317000_21.2.240176.51","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15531"}],"container-title":["Breathe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/20734735.0176-2024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T08:35:23Z","timestamp":1744878923000},"score":1,"resource":{"primary":{"URL":"http:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/20734735.0176-2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,4,17]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1183\/20734735.0176-2024"],"URL":"https:\/\/doi.org\/10.1183\/20734735.0176-2024","relation":{},"ISSN":["1810-6838","2073-4735"],"issn-type":[{"value":"1810-6838","type":"print"},{"value":"2073-4735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}